Last reviewed · How we verify

umeclidinium bromide and vilanterol trifenatate — Competitive Intelligence Brief

umeclidinium bromide and vilanterol trifenatate (umeclidinium bromide and vilanterol trifenatate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA). Area: Respiratory / Pulmonolo

marketed Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor and beta-2 adrenergic receptor Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

umeclidinium bromide and vilanterol trifenatate (umeclidinium bromide and vilanterol trifenatate) — Chiesi Farmaceutici S.p.A.. Umeclidinium is a long-acting muscarinic antagonist and vilanterol is a long-acting beta-2 agonist that together relax airway smooth muscle and improve airflow in chronic obstructive pulmonary disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
umeclidinium bromide and vilanterol trifenatate TARGET umeclidinium bromide and vilanterol trifenatate Chiesi Farmaceutici S.p.A. marketed Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor and beta-2 adrenergic receptor
GSK573719/VI 125/25 GSK573719/VI 125/25 GlaxoSmithKline phase 3 LAMA/LABA combination (long-acting muscarinic antagonist/long-acting beta-2 agonist) M3 muscarinic receptor and beta-2 adrenergic receptor
TIO/OLO TIO/OLO GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor and beta-2 adrenergic receptor
UMEC/VI DPI UMEC/VI DPI GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor (umeclidinium); Beta-2 adrenergic receptor (vilanterol)
Revefenacin 175 µg, Formoterol 20 µg Revefenacin 175 µg, Formoterol 20 µg University of Tennessee Graduate School of Medicine marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor
UMEC/VI UMEC/VI GlaxoSmithKline marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) Muscarinic M3 receptor; beta-2 adrenergic receptor
Umeclidinium/Vilanterol 62.5/25 mcgs Umeclidinium/Vilanterol 62.5/25 mcgs National Institute of Respiratory Diseases, Mexico marketed Long-acting muscarinic antagonist / long-acting beta-2 agonist combination (LAMA/LABA) M3 muscarinic receptor; beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting muscarinic antagonist / Long-acting beta-2 agonist combination (LAMA/LABA) class)

  1. Chiesi Farmaceutici S.p.A. · 1 drug in this class
  2. Gary L. Pierce · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). umeclidinium bromide and vilanterol trifenatate — Competitive Intelligence Brief. https://druglandscape.com/ci/umeclidinium-bromide-and-vilanterol-trifenatate. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: